News

News and Events

  • HemaFlo Therapeutics Provides Update on Global Patent Portfolio

    Portfolio includes patents for treating acute kidney injury in the U.S., EU, Japan and Australia

    CARLSBAD, Calif., May 20, 2020 – HemaFlo Therapeutics Inc. today provided an update on its patent portfolio covering the use of drag-reducing polymers for the treatment of acute kidney injury (AKI). The company now has intellectual property coverage in the largest markets globally and is working to advance the development of its technology for AKI, which is a debilitating and unintended consequence of hospitalization.

    Most recently, the European Patent Office granted to HemaFlo a patent with broad claims (number 2765984 granted July 31, 2019). In doing this, the European Patent Office concurred
    with the Japanese Patent Office, which had granted patent number 6131258 on April 21, 2017, and with the Australian Patent Office, which granted patent 2012323364 on April 6, 2017. These patents are in addition to those granted by the U.S. Patent Office (US 9,119,880

    Read more

  • HemaFlo Therapeutics Announces Issuance of Key Patent for HFT-012

    Broad claims cover use of HFT-012 to treat Acute Kidney Injury

    Carlsbad, CA, February 14, 2017 — HemaFlo Therapeutics, Inc. announced today the United States Patent and Trademark Office (USPTO) has issued US Patent Number 9,566,298 covering the use of HFT-012 to treat acute kidney injury (AKI).

    Dale Peterson, PhD, HemaFlo’s founder, said, “We are pleased to secure our rights to such a powerful technology.”

    HFT-012 is a proprietary product that contains a Drag Reducing Polymer (DRP) with the potential to improve vascular perfusion and reduce the complications associated with AKI. In a rat model of ischemic AKI, HFT-012 demonstrated a statistically significant improvement in kidney function.

    The initial indication for HFT-012 will be in post-surgical patients who have early stage AKI. Treatment with HFT-012 is intended to increase perfusion of the kidneys and reduce the complications, morbidities and mortalities associated with prolonged and advanced-stage AKI. In the longer term, HFT-012

    Read more

  • Michael Martino Named President and Chief Executive Officer of HemaFlo Therapeutics

    Industry veteran brings operating expertise to development-stage company focused on delivering therapies for diseases caused by poor blood flow

    Carlsbad, CA, January 18, 2016 — HemaFlo Therapeutics, Inc. announced today the appointment of Michael A. Martino as President, Chief Executive Officer and a member of the Board of Directors. Mr. Martino was most recently President and Chief Executive Officer of Ambit Biosciences until its acquisition by Daiichi Sankyo.

    Dale Peterson, PhD, HemaFlo’s founder, said, “We are pleased to attract a seasoned executive with expertise in building and leading teams, developing innovative strategies that create value, executing deals and raising capital in the private and public sectors. Michael’s experience is vital to HemaFlo as we take the next steps to accelerate the development of NephroFlow, our lead product for the treatment of acute kidney injury.”

    “I am pleased to collaborate with a talented entrepreneur like Dale who has successfully commercialized more than

    Read more

  • DRP Biomedical Is Now HemaFlo Therapeutics

    Change highlights company mission to develop therapies for diseases characterized by poor blood flow

    Carlsbad, CA, January 18, 2016 — DRP Biomedical, Inc., announced today that it has changed its corporate name to HemaFlo Therapeutics, Inc., to highlight the company’s mission to develop therapies for diseases characterized by poor blood flow or ischemia.

    “DRP is an acronym for our core Drag Reducing Polymer technology,” said Michael A. Martino, HemaFlo’s President and Chief Executive Officer.

    “We believe this technology has broad applicability in a number of acute and chronic disease states that are associated with decreased tissue perfusion due to reduced blood flow. The HemaFlo Therapeutics name more completely reflects our broader mission to develop therapies for these diseases, and DRP will continue to be used to describe our technology.”

    The initial application of HemaFlo’s DRP technology is reflected in HFT-012, the company’s lead product in preclinical development to treat acute kidney injury (AKI),

    Read more

HemaFlo Therapeutics © 2016